BOLT Bolt Bio: רווח נקי למניה ב-12 החודשים האחרונים

Bolt Biotherapeutics focuses on the safety of ISAC-conjugates for combating tumors. The business is underpinned by robotic test automation, as evidenced by the year-over-year (ttm) EPS trend, where the current value stands at 33.30. The company is currently minimizing expenses and developing only one primary drug, while excluding any merger and acquisition deals.
boltbio.com - פילוחים אנליטיים ומדדי מפתח (BOLT)

This indicator measures the dynamics of net income per share over a rolling year, stripping fundamental metrics of short-term market noise. For Bolt Biotherapeutics (BOLT), which focuses on costly immunotherapy research without current revenues, the current EPS YoY TTM growth trend reflects the impact of capital injections and clinical costs, determining the company's overall capital resilience.